Metabolic Imaging in Parkinson Disease

J Nucl Med. 2017 Jan;58(1):23-28. doi: 10.2967/jnumed.116.183152. Epub 2016 Nov 22.

Abstract

This review focuses on recent human 18F-FDG PET studies in Parkinson disease. First, an overview is given of the current analytic approaches to metabolic brain imaging data. Next, we discuss how 18F-FDG PET studies have advanced understanding of the relation between distinct brain regions and associated symptoms in Parkinson disease, including cognitive decline. In addition, the value of 18F-FDG PET studies in differential diagnosis, identifying prodromal patients, and the evaluation of treatment effects are reviewed. Finally, anticipated developments in the field are addressed.

Keywords: FDG-PET; Parkinson’s disease; imaging; metabolism; networks.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Brain / diagnostic imaging
  • Brain / metabolism*
  • Brain Mapping / methods*
  • Cognitive Dysfunction / diagnosis
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / metabolism
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Glucose / metabolism*
  • Humans
  • Image Interpretation, Computer-Assisted / methods
  • Molecular Imaging
  • Parkinson Disease / complications
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / metabolism*
  • Radiopharmaceuticals / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Glucose